Clinical Trial News - Pivotal Clinical Trial for Large B-Cell Lymphoma first patient enrolled – excited about potential outcomes

Virginia Cancer Specialists Practice Blog

August 07, 2018
Virginia Cancer Specialists » VCS Practice News » Blog Post » Clinical Trial News – Pivotal Clinical Trial for Large B-Cell Lymphoma first patient enrolled – excited about potential outcomes

ADC Therapeutics Doses First Patient in Pivotal Clinical Trial of ADCT-402 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase II trial evaluating efficacy and safety of CD19-targeting antibody drug conjugate intended to support submission of Biologics License Application
Top-line data expected in third quarter of 2019

Lausanne, Switzerland, August 7, 2018 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase II clinical trial intended to support the submission of Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). The clinical trial is evaluating the efficacy and safety of ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). More Here ADCT-402_Phase_2_FPD_DLBCL_Release_7.8.2018 (002)

Award Winning Physicians

Our Physicians work for you, ensuring the highest standard of care.

Learn More